Search results
Neuralink Rival Backed By Jeff Bezos And Bill Gates Broadens Horizons With Plans To Treat Parkinson'...
Benzinga· 5 days agoWhat Happened: On Thursday at the Bloomberg Tech Summit, Synchron’s founder, Tom Oxley, disclosed...
Halia Therapeutics to Unveil New Clinical Program Targeting the LRRK2 Protein for Alzheimer's ...
The Herald Journal· 14 hours agoCEO David J. Bearss, Ph.D., will be participating in a panel discussing the "Landscape of Drug Discovery and Impact of AI Discussion" on Wednesday, May 22, from 1:50 to 2:30
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
FOX 59 Indianapolis· 10 hours ago(Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare ...
Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst St
Guru Focus· 4 days agoSupernus Pharmaceuticals is at the forefront of developing and commercializing products to treat central nervous system disorders, including epilepsy, ADHD, and Parkinson' ...
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
Digital Journal· 6 hours agoTop-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024CAMBRIDGE, Massachusetts ...
‘Sandwich generation’: How Raleigh family built an ADU for aging parents in their yard
Raleigh News and Observer via AOL· 4 days agoThe Millhausers, meanwhile, are settling into their new lives. Both have signed up for continuing...
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
Zacks via Yahoo Finance· 6 days agoPipeline Updates In March 2024, Acadia announced the failure of its late-stage study evaluating...
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International...
Benzinga· 14 hours agoMr. Glover welcomes one-on-one meetings to discuss ZyVersa's technology, pipeline assets, and key development milestones. WESTON, Fla., May 14, 2024 (GLOBE...ZyVersa Therapeutics ...
IRLAB Publishes Interim Eeport for the Period January-March 2024
Digital Journal· 7 days agoFigures in brackets = same period 2023, unless otherwise stated.
Coya Therapeutics Reports First Quarter 2024 Financial Results
Guru Focus· 4 days agoThe Houston-based clinical-stage biotechnology company reported a net loss of $5.1 million, which did not align with analyst expectations of a $4.43 million loss. Coya Therapeutics ...